Innate Pharma (ADR) (IPHA)
Develops innate-immunity-based antibody therapies for cancer alongside AstraZeneca and Sanofi collaborations.
$1.76
vs last close−0.04 (−2.22%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Sep '23May '24Nov '24May '25Sep '25Nov '25May '26Sep '26
Reported$0.02−$0.13−$0.34−$0.35−$0.29−$0.30−$0.35−$0.24
Estimate$0.09−$0.44−$0.30−$0.27−$0.14−$0.33−$0.35−$0.29
Surprise−75.2%+70.1%−14.0%−29.5%−106.5%+9.8%+0.8%+18.1%
RevenueReportedEstimate
Sep '23May '24Nov '24May '25Sep '25Nov '25May '26Sep '26
Reported$42.9M$23.2M$13.6M$8.7M$5.7M$5.8M$4.8M$6.5M
Estimate$68.6M$18.2M$13.3M$18.2M$2.0M$2.3M$5.7M$6.4M
Surprise−37.5%+28.0%+2.5%−52.5%+192.0%+148.2%−16.1%+2.4%
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$0.24 | — | — |
| Sep 2026 | −$0.29 | −$0.24 | +18.1% |
| May 2026 | −$0.35 | −$0.35 | +0.8% |
| Nov 2025 | −$0.33 | −$0.30 | +9.8% |
| Sep 2025 | −$0.14 | −$0.29 | −106.5% |
| May 2025 | |||
| Nov 2024 | |||
| May 2024 | |||
| Sep 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Mar 2022 | |||
| Sep 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| May 2020 | |||
| Sep 2020 | |||
| Nov 2019 | |||
| Mar 2020 | |||
| May 2019 | |||
| Sep 2019 | |||
| Jun 2018 | |||
| Dec 2017 | |||
| Jun 2017 | |||
| Dec 2016 | |||
| Jun 2016 | |||
| Dec 2015 | |||
| Jun 2015 | |||
| Dec 2014 | |||
| Jun 2014 | |||
| Dec 2013 | |||
| Jun 2013 | |||
| Dec 2012 | |||
| Jun 2012 | |||
| Dec 2011 | |||
| Jun 2011 | |||
| Dec 2010 | |||
| Jun 2010 | |||
| Dec 2009 | |||
| Jun 2009 | |||
| Dec 2008 | |||
| Jun 2008 | |||
| Dec 2007 | |||
| Jun 2007 | |||
| Dec 2006 | |||
| Jun 2006 | |||
| Dec 2005 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2026 | −$0.24 | — | — | $2.0M | — | — | — |
| Sep 17, 2026 | −$0.29 | −$0.24 | +18.1% | $6.4M | $6.5M | +2.4% | −5.0% |
| May 13, 2026 | −$0.35 | −$0.35 | +0.8% | $5.7M | $4.8M | −16.1% | −2.9% |
| Nov 13, 2025 | −$0.33 | −$0.30 | +9.8% | $2.3M | $5.8M | +148.2% | −5.2% |
| Sep 17, 2025 | −$0.14 | −$0.29 | −106.5% | $2.0M | $5.7M | +192.0% | −5.4% |
| May 13, 2025 | |||||||
| Nov 13, 2024 | |||||||
| May 14, 2024 | |||||||
| Sep 14, 2023 | |||||||
| Mar 23, 2023 | |||||||
| Sep 15, 2022 | |||||||
| Mar 24, 2022 | |||||||
| Sep 15, 2021 | |||||||
| Mar 18, 2021 | |||||||
| Nov 17, 2020 | |||||||
| May 12, 2020 | |||||||
| Sep 8, 2020 | |||||||
| Nov 13, 2019 | |||||||
| Mar 10, 2020 | |||||||
| May 15, 2019 | |||||||
| Sep 13, 2019 | |||||||
| Jun 30, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Jun 30, 2015 | |||||||
| Dec 31, 2014 | |||||||
| Jun 30, 2014 | |||||||
| Dec 31, 2013 | |||||||
| Jun 30, 2013 | |||||||
| Dec 31, 2012 | |||||||
| Jun 30, 2012 | |||||||
| Dec 31, 2011 | |||||||
| Jun 30, 2011 | |||||||
| Dec 31, 2010 | |||||||
| Jun 30, 2010 | |||||||
| Dec 31, 2009 | |||||||
| Jun 30, 2009 | |||||||
| Dec 31, 2008 | |||||||
| Jun 30, 2008 | |||||||
| Dec 31, 2007 | |||||||
| Jun 30, 2007 | |||||||
| Dec 31, 2006 | |||||||
| Jun 30, 2006 | |||||||
| Dec 31, 2005 |